Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M54.0Revenue $M17.4Net Margin (%)-89.6Altman Z-Score-4.2
Enterprise Value $M15.4EPS $-0.2Operating Margin %-90.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-89.6Higher ROA y-yN
Price/Book1.110-y EBITDA Growth Rate %-17.6Quick Ratio10.2Cash flow > EarningsY
Price/Sales3.15-y EBITDA Growth Rate %-15.0Current Ratio10.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-27.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-29.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M91.4ROIC % (ttm)-176.7Gross Margin Increase y-yY

Gurus Latest Trades with VICL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VICLJohn Rogers 2015-06-30 Add$0.7 - $1.48
($0.99)
$ 0.59-40%Add 7.21%7,460,515
VICLJohn Rogers 2015-03-31 Add$0.86 - $1.17
($1.02)
$ 0.59-42%Add 7.34%6,958,945
VICLGeorge Soros 2014-09-30 Sold Out $1.12 - $1.31
($1.24)
$ 0.59-52%Sold Out0
VICLGeorge Soros 2014-06-30 Buy $1.12 - $1.35
($1.19)
$ 0.59-50%New holding58,179
VICLJohn Rogers 2013-12-31 Add0.03%$1.015 - $1.49
($1.2)
$ 0.59-51%Add 39.31%7,062,104
VICLJohn Rogers 2013-06-30 Add0.13%$2.93 - $4.22
($3.52)
$ 0.59-83%Add 93.26%5,134,817
VICLJohn Rogers 2013-03-31 Add0.08%$2.91 - $4.26
($3.54)
$ 0.59-83%Add 71.60%2,656,967
VICLJohn Rogers 2012-12-31 Add0.03%$2.74 - $4.32
($3.31)
$ 0.59-82%Add 49.50%1,548,357
VICLJohn Rogers 2012-03-31 Add0.01%$3.02 - $4.28
($3.23)
$ 0.59-82%Add 26.34%877,193
VICLJohn Rogers 2011-06-30 Reduce-0.01%$2.88 - $4.81
($3.75)
$ 0.59-84%Reduce 30.97%577,773
VICLJohn Rogers 2010-09-30 Add0.03%$2.21 - $3.86
($3.2)
$ 0.59-82%Add 548.18%795,728
VICLJohn Rogers 2009-06-30 Buy 0.01%$1.95 - $2.76
($2.28)
$ 0.59-74%New holding137,198
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VICL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VICL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ramos Anthony AlanVP, Chief Accounting Officer 2015-07-23Sell194$0.62-4.84view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2015-07-13Sell974$0.7-15.71view
SAMANT VIJAY BPresident & CEO 2015-07-13Sell4,737$0.7-15.71view
BILINSKY IGORSr VP, Corporate Development 2015-07-13Sell1,258$0.7-15.71view
Ramos Anthony AlanVP, Chief Accounting Officer 2015-04-23Sell193$1.01-41.58view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2015-04-13Sell974$0.93-36.56view
BILINSKY IGORSr VP, Corporate Development 2015-04-13Sell1,257$0.93-36.56view
SAMANT VIJAY BPresident & CEO 2015-04-13Sell4,738$0.93-36.56view
SAMANT VIJAY BPresident & CEO 2015-03-30Sell55,000$0.91-35.16view
Ramos Anthony AlanVP, Chief Accounting Officer 2015-01-21Sell428$1.09-45.87view

Quarterly/Annual Reports about VICL:

    News about VICL:

    Articles On GuruFocus.com
    Red Hat (RHT) and Five Below (FIVE) Strong Performance Metrics; Vical (VICL) Targets Multi-billion S Mar 26 2015 
    John Rogers Comments on Vical Feb 26 2014 
    Kids Decide on Dolls or Devices - JAKK, Others 70% Off Sep 17 2013 
    comment on VICL Mar 02 2013 
    Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 
    Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade Jan 17 2013 
    Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
    Vical Inc. (VICL) CEO Vijay B Samant buys 1,000 Shares Jan 20 2011 
    Vical Inc. Reports Operating Results (10-Q) Aug 06 2010 
    Vical Inc. Reports Operating Results (10-Q) May 07 2010 

    More From Other Websites
    Vical's Antifungal Candidate VL-2397 Receives QIDP Status Aug 20 2015
    FDA Grants Qualified Infectious Disease Product (QIDP) Designation to VL-2397, Vical's Antifungal... Aug 19 2015
    FDA Grants Qualified Infectious Disease Product (QIDP) Designation to VL-2397, Vical's Antifungal... Aug 19 2015
    VICAL INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... Aug 07 2015
    VICAL INC Financials Aug 06 2015
    10-Q for Vical, Inc. Aug 01 2015
    Vical reports 2Q loss Jul 30 2015
    Vical reports 2Q loss Jul 30 2015
    Vical Reports Second Quarter 2015 Financial Results and Progress in Key Development Programs Jul 30 2015
    VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 30 2015
    Vical Reports Second Quarter 2015 Financial Results and Progress in Key Development Programs Jul 30 2015
    Vical Announces News Release and Conference Call Schedule for Second Quarter 2015 Financial Results Jul 23 2015
    Vical Announces News Release and Conference Call Schedule for Second Quarter 2015 Financial Results Jul 23 2015
    The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases Jun 25 2015
    Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog Jun 24 2015
    Vical Looks a Lot Less Vital Jun 24 2015
    Vical downgraded by ROTH Capital Jun 23 2015
    Vical's Herpes Vaccine Didn't Meet Primary Endpoint Jun 22 2015
    Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine Jun 22 2015
    VICAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 22 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK